Calcium phosphate-based nanosystems for advanced targeted nanomedicine

Lorenzo Degli Esposti, Francesca Carella, Alessio Adamiano, Anna Tampieri and Michele Iafisco

Institute of Science and Technology for Ceramics (ISTEC), National Research Council (CNR), Faenza, Italy

ABSTRACT

Synthetic calcium phosphates (CaPs) are the most widely accepted bioceramics for the repair and reconstruction of bone tissue defects. The recent advancements in materials science have prompted a rapid progress in the preparation of CaPs with nanometric dimensions, tailored surface characteristics, and colloidal stability opening new perspectives in their use for applications not strictly related to bone. In particular, the employment of CaPs nanoparticles as carriers of therapeutic and imaging agents has recently raised great interest in nanomedicine. CaPs nanoparticles, as well as other kinds of nanoparticles, can be engineered to specifically target the site of the disease (cells or organs), thus minimizing their dispersion in the body and undesired organism-nanoparticles interactions. The most promising and efficient approach to improve their specificity is the ‘active targeting’, where nanoparticles are conjugated with a targeting moiety able to recognize and bind with high efficacy and selectivity to receptors that are highly expressed only in the therapeutic site. The aim of this review is to give an overview on advanced targeted nanomedicine with a focus on the most recent reports on CaP nanoparticles-based systems, specifically designed for the active targeting. The distinctive characteristics of CaP nanoparticles with respect to the other kinds of nanomaterials used in nanomedicine are also discussed.

Introduction

Nanomedicine

Modern medicine is currently undergoing a paradigm shift from the conventional disease managements to more personalized and customized treatments, exploiting specific interactions of therapeutic agents at molecular level. In this domain, encouraging results come from the emerging field of nanomedicine, which is defined as the application of nanotechnology to address healthcare problems, where the unique and novel properties displayed by nanomaterials are harnessed to achieve performances, specificity, and biological activities not exhibited by their counterparts at larger dimensional scales [1–3].

The nanometric dimensions of nanoparticles/nanosystems (that are described here by the generic abbreviation ‘NPs’) confer several advantages when they are employed as drug nano-carriers or even as therapeutic agents. For example, water dispersed NPs can encapsulate hydrophobic drugs, increasing drug bioavailability and at the same time offering protection against in vivo drug early degradation [4]. The nanometric size allows NPs to escape the capture by cells of the reticuloendothelial system (RES) avoiding the rapid clearance and improving the circulation time [5]. At the same time, the small size allows their penetration into tissues and cells to reach the target site [6]. The use of NPs has been mainly studied for cancer management, and several clinically approved NPs-based formulations for the treatment of a variety of cancer types exist nowadays [3,7–9]. Several authors have pointed out that innovative NPs-mediated formulations of conventional chemotherapeutics can enhance their efficacy [10,11]. In addition, the conjugation of antineoplastic drugs with NPs can reduce their side effects (i.e. cardiotoxicity, nephrotoxicity, and hepatotoxicity) by minimizing their non-specific interactions with healthy cells and tissues [12–17]. The application of NPs to treat other diseases such as cardiovascular, neurological, and musculoskeletal ones has been more recently investigated [18–21].

In most of the studies, NPs act as mere carriers of biologically active molecules, and their role is to bind and deliver to the site of the disease conventional or innovative therapeutic agents [4,22,23]. In other cases, the composition and the intrinsic characteristics of NPs can be exploited in combination with external stimuli to exert a therapeutic effect. This is the case for example of photodynamic, hyperthermia, and neutron capture therapies that have been developed employing drug-free NPs [24–31].

The use of NPs as imaging probes for cells and tissue has also been extensively explored in the last decade in virtue of several advantages provided over conventional imaging agents. Materials at the nano scale possesses unique optical, magnetic, and chemical properties that allow the creation of imaging probes with increased density, amplification, and quantification of the signal, as well as with improved contrast, compared to conventional imaging agents [11,32]. In this domain, NPs are efficiently used as imaging agents in magnetic resonance imaging (MRI) [33], positron emission tomography (PET) [34], near-infrared (NIR) adsorption [35], or in combinations of them as in the case of dual-imaging techniques (i.e. a combination of MRI and PET) [36].

NPs can also be designed to work as ‘theranostic’ agents, designed to exert at the same time both diagnostic and therapeutic functions, thus enabling the non-invasive in vivo real-time monitoring of the therapy efficiency [11,37–39]. The monitoring of NPs behavior is essential to clearly assess their bio-distribution, namely tissue penetration, organ accumulation, and excretion; these information are the key-points of important
pharmacodynamics aspects of NPs such as hematic lifetime, drug delivery kinetic, toxicity, specificity, and efficacy [37].

The generation of theranostic agents is at the forefront of medicine in virtue of the possibility to achieve controlled and localized therapeutic actions. In particular, the development of effective theranostic NPs is a milestone of ‘personalized’ or ‘precision’ medicine that aims to set up ad hoc patient-specific disease managements. Personalized medicine could achieve the tuning of patients treatment accordingly to the specific situation, i.e. tailoring of key pharmacological parameters such as drug dosage, number of treatments, drug relapse control etc. Therefore, the personalized approach will enable to maximize the therapeutic action and at the same time to minimize side effects and discomfort [40,41].

We must caution the reader that all that glitters is not gold, as long-term toxicity of several kinds of NPs has not been elucidated yet; thus, their capacity to penetrate into tissues could become a double-edged sword as non-biodegradable NPs can accumulate also in healthy tissues inducing inflammatory and toxic effects [42,43]. In order to overcome these drawbacks and to improve their efficiency, NPs must be engineered to be ‘targeted’ towards the site of the disease (cells or organs), thus minimizing NPs dispersion in the organism and undesired organism-NPs interactions [44].

**Targeted nanomedicine**

There are several approaches to turn non-specific NPs into targeted ones. Firstly, it must be mentioned that NPs are naturally targeted for tumors through the enhanced permeation and retention (EPR) effect, consisting in their spontaneous accumulation in the leaky and over-vascularized cancerous tissues [45]. However, this form of ‘passive targeting’ is not always efficient because the degree of tumor vascularization and porosity of tumor vessels can vary within tumor types and conditions [46,47]. Besides, in non-cancerous diseases, the EPR effect does not occur.

The most promising and efficient approach to improve the specificity of NPs is the ‘active targeting’, where a targeting moiety is added as surface decoration to the NPs, that may provide additional or alternative delivery mechanisms to EPR.

The targeting moiety is a molecule/macromolecule capable to recognize and bind with high efficacy and selectivity to receptors expressed only by specific cells [48,49]. Once the NPs functionalized with the targeting molecules arrive near the target cells, they interact with membrane receptors via ‘targeting moiety-receptor’ mechanisms and, in some cases, penetrate in the cells by specific receptor-mediated internalization processes. Consequently, NPs release their therapeutic payload in close proximity or inside the target cells (Figure 1) [48–50].

Since cancer is one of the leading causes of morbidity and mortality worldwide, the development of targeted NPs has mainly focused on tumor treatment. Specifically, death from cancer amounts to about 13% of total deaths per year (i.e. an average of 4.2 million men and 3.4 million women) and is expected to reach 13.1 million deaths in 2030 [51,52]. The main issue of cancer disease is tied to the large and radical variety of tumors; therefore an ideal and efficient cancer therapy should be type-specific and selective [3,48,53–55]. In this regard, it is worth to mention that the research on targeted NPs for the management of cardiac, neurological, and others diseases has also started but is still in its infancy [56–58].

![Image](Image.png)

**Figure 1.** Schematic representation of the active targeting mechanism.

The study of targeted NPs is at the moment a hot topic in the scientific research and the number of publications in this field has grown exponentially in the last two decades (Figure 2(A)). Moreover, this topic is multidisciplinary and involves different subjects such as nanotechnology, chemistry, molecular biology, pharmacology, etc. (Figure 2(B)).

**Active targeting moieties**

Several targeting moieties and functionalization procedures have been exploited to achieve active targeted NPs [50,59–61]. The most studied and effective targeted moieties include: monoclonal antibodies [62], antibody derivatives [63], peptides [64,65], aptamers [66], transferrin [67–69], carbohydrates [60,70], and small organic molecules [71,72].

Monoclonal antibodies (mAbs) are single macromolecular species that bind to their specific antigens with high affinity and selectivity (in general, they can bind to only one specific target), and can be precisely designed to target a plethora of receptors [73]. However, the use of mAbs suffers from several limitations, such as (i) large molecular size, (ii) difficulties in the conjugation with NPs, and (iii) highly expensive production processes [62,74]. Moreover, mAbs often are derived from animals, therefore their administration could result in an immune response. However, mAbs derived from murine proteins can be manipulated into humanized versions that can provoke low to no immune response, but on the other hand, this requires high-production costs [62,75].

Antibody derivatives are an interesting alternative, as they are smaller, cheaper and less immunogenic than mAbs while holding comparable affinity and selectivity [63]. These derivatives – sometimes called ‘nanobodies’ – are naturally-derived or synthetic antigen-binding fragments (called Fab or Fab’), and usually retain the specific antigen-binding affinity of the parent mAbs while displaying improved tissue penetration [63].

Peptides and aptamers are targeting moieties consisting of small sequences of amino acids and nucleic acids, respectively. Their selection strategy is based on combinatorial peptide/aptamers libraries, consisting of random or systematic collections of oligopeptides/oligonucleotides chains. These libraries are tested against the binding target and only the molecules that possess targeting capability are selected and amplified (i.e. mass produced). In this regard, the reader can refer to several reviews treating in detail this strategy [76–80]. The use of peptides and aptamers allows to reduce the synthesis cost of highly specific
targeting moieties with relatively low-molecular size and low immunogenicity [65, 66, 79]. The targeting capacity of aptamers is mainly due to their three-dimensional conformation deriving from their nucleotide sequence [81, 82]. To maximize aptamer efficacy, whole living cells, pathogens, or even animal models are used as targets for aptamer selection and amplification [66]. Some aptamers can also promote NPs internalization enhancing the efficacy of the therapeutic agent [83–85]. However, they are prone to enzymatic degradation in the biological environment that could lead to a rapid loss of their targeting capability. To overcome this issue, aptamers can be chemically modified with small molecules or with polyethylene-glycol (PEG) polymers to improve their bioavailability and pharmacokinetic properties [86, 87].

As for aptamers, a number of peptides that specifically target various tissues under normal or pathological conditions have been already identified [88]. Similarly, some proteins have the function of binding selectively to specific membrane receptors expressed by several types of cells, and the specific peptidic fragments that are involved in the binding process can be exploited as targeting peptides. A notorious example of these peptidic fragments is the arginyl-glycyl-aspartic acid (RGD) tripeptide, a sequence identified in fibronectin glycoprotein that binds to cell surface receptors known as integrins. One of the most interesting integrin is αvβ3, which is implicated in tumor angiogenesis and is the target for numerous RGD-functionalized NPs [89].

Organic molecules used as targeting moieties usually exploit the natural overexpression of their receptors in unhealthy tissues, as in the case of folate–folic acid specific – and of transferrin–transferrin specific – receptors in solid tumors [67–69, 72, 90]. Folate is the water-soluble form of vitamin B9 and is essential in humans for rapid cell division and growth, especially during the embryonic development [91]. Folate receptors are overexpressed in ovarian, brain, head, neck, renal, and breast tumor cells; thus folate, which has a high-binding affinity for its receptor (Kd = 10^7 M), was widely employed as targeting moieties of imaging and therapeutic agents to tumors [92, 93]. Transferrin is a membrane glycoprotein that binds and transports iron ions in the serum to cells via transferrin receptor (TfR) [94, 95]. As in the case of folate, when transferrin binds to its receptor, it initiates the endocytosis and gets internalized into the cytoplasm [94, 95]. Due to the higher rate of proliferation of tumor cells compared to healthy ones, the transferrin receptor is ten-fold overexpressed in cancerous tissue as a consequence of the dramatic increase of iron requirement. Therefore, the increased expression of TfR makes transferrin an attractive targeting agent for the delivery of chemotherapeutics via nanocarriers [86, 89, 96].

Some carbohydrate receptors are overexpressed too in diseased cells; for example, galactose has a high affinity for asialoglycoprotein receptors found on hepatocytes (with a density of 500,000 receptors per cell) [97, 98]. Hyaluronic acid, a copolymer of N-acetyl D-glucosamine and D-glucuronic acid, can bind selectively to the cluster determinant 44 (CD44), a transmembrane protein, which plays a crucial role in the activities associated with various malignant tumors [99–102].

Several of the above-mentioned targeting moieties (e.g. mAbs, aptamers, etc.) are available in the market in the conjugated forms with imaging probes to monitor their biodistribution [103, 104]. The surface decoration of NPs with targeting molecules can be achieved by several means ranging from physisorption to the formation of new chemical bonds; among them, click reactions and the use of capture nucleotide strands are two particularly effective methods [105–113]. Indeed, targeting moieties are effective only if their molecular binding region is free to recognize the receptor. Therefore, the formation of a rigid chemical bond between NPs and a non-active region of the targeting agent is the best method to have a precisely control over the orientation of the moieties. While the use of click reactions is a well-known conjugation method, the use of capture nucleotide strands is a newer approach [113, 114]. With this latter methodology, also known as nucleotide hybridization method, nucleotide single strands are attached to the NPs and the complementary strands are conjugated to the targeting moieties. The coupling between NPs and targeting agents consists of the nucleotide hybridization, that is the formation of a double strand between the nucleotides of NPs and those of the targeting agents [114–117].

A multitude of organic, inorganic, and hybrid NPs have been functionalized with active targeting moieties – mainly for cancer therapy – and several review papers have been published on this topic [3, 10, 11, 48–50, 53, 54, 59, 81, 91]. Among them, calcium phosphates (CaPs) have been proved to be one of the most promising materials in nanomedicine. Several reviews on the use of CaP NPs for general nanomedical applications were already published [39, 118–124], therefore in the next paragraphs are discussed the most recent and significant reports on CaP NPs, specifically designed for the active targeting on the basis of a large literature survey. In addition, an overview about the peculiar characteristics of CaP NPs with respect to the other kinds of nanomaterials currently studied in nanomedicine is also reported.
The role of calcium phosphate nanoparticles in nanomedicine

Chemical and biological properties

In biological systems, CaPs are the inorganic constituent of normal (bone, dentin, fish scales, horns of different animals) and pathological (e.g. dental and some urinary calculi, tendon mineralization, calcification of blood vessels) calcifications [119]. Apart from enamel, which has a high degree of crystallinity, they occur mainly in the form of ionic substituted and poorly crystallineapatites. Nanocrystallineapatites, in contrast to stoichiometric hydroxyapatite (HA) [Ca_{10}(PO_{4})_{6}(OH)_{2}] which is the most thermodynamically stable and least soluble CaP phase in physiological conditions, are nonstoichiometric (Ca/P ratio less than 1.67), nanometric in size (length 20–50 nm, width 15–30 nm, and thickness 1.5–4 nm), calcium (and OH−)-deficient, and can incorporate substituted ions in its crystall lattice (i.e. Na+, Mg2+, K+, F−, CO32−, etc.) [120,121].

Due to their excellent biological properties, such as biocompatibility, bioactivity, osteoconductivity, osteoinductivity, and non-immunogenicity, synthetic CaPs are the most important compounds to prepare biomedical devices for hard tissue substitution and regeneration, in the form of three-dimensional dense or porous ceramics and as injectable cements [122–137].

The recent advancements in materials science and nanotechnology have prompted a rapid progress in the preparation of CaPs with tailored surface characteristics, nanometric dimensions, and colloidal stability in aqueous environment opening new interesting perspectives in different biomedical fields [138,139].

A huge number of synthetic routes exist for CaP NPs preparation and they have been extensively reviewed by other authors [122–137]. Due to the different strategies employed up to now, the classification of the synthesis methods is very difficult and deserves dedicated review papers. Probably, the simplest way to rationally classify the CaP NPs crystallization methods is the discrimination between the processes using high or low temperature. The synthetic methods at low temperature are preferred with respect to those involving higher temperature (>100 °C) because they offer the advantage to produce CaP NPs having features very close to the biological ones. Biomimetic CaPs are the most appealing CaP NPs for medical applications as they are better tolerated by organisms with respect to sintered ones [140]. The reason of this behavior is that they are similar in terms of chemical composition, crystal structure, and morphology to the mineral phase of bone that makes them recognizable by organisms as a sort of endogenous materials.

The use of organic compounds as templates for the generation of CaP with nano-sized dimensions and biomimetic features is another interesting strategy that has received increasing attention over the last decade. For example, the role of citrate ions in controlling and stabilizing the size of CaP NPs is a biologically inspired synthetic strategy that was recently efficiently developed [141–145]. In general, the synthesis of biomimetic CaP NPs with respect to the principles of green chemistry, for example they are not carried out in organic or hazardous solvent and they are cheap and easy to be scaled up [119,123,134,135]. These conditions are often not met in the production of other kinds of inorganic or organic NPs [146–156].

One of the most important characteristic of CaP NPs is that they are degraded faster with respect to the most commonly used inorganic NPs (i.e. quantum dots, silica, magnetic NPs, and carbon nanotubes) and in addition, their degradation is followed by the release of the non-toxic calcium and phosphate ions [157,158].

From a chemical point of view, another great advantage of CaP NPs is that their chemical composition (i.e. Ca/P ratio, anionic, or cationic substituents), hydration level, crystallinity degree, dimension, morphology, aspect ratio, polydispersity index, surface area, surface charge, and colloidal stability can be tailored by changing synthesis parameters [134,135,159].

Moreover, CaP NPs for nanomedical use, in particular HA, have a highly flexible crystal lattice able to accommodate (doping) several substituting ions while retaining their intrinsic structure. Doping can impart peculiar functionalities (such as luminescence, magnetism, hyperthermia), or can exert specific action when in contact with the biological environment such as antitumor and antibacterial ones [30,160–167]. For example, CaP NPs doped with fluorescent and luminescent cations, radionuclides, magnetic, or antibacterial ions have been extensively reported [118].

CaP NPs are promising vectors for drug delivery since they can load a high variety of bioactive molecules on their surface or encapsulate biomolecules within the particle, thus protecting the therapeutic agent from degradation in the biological environment [145]. Furthermore, CaP NPs possess a pH-dependent solubility as they are stable in physiological conditions and in blood plasma (pH 7.4), but are easily degraded in biological acidic environments (pH <5) as that found in inflammatory regions or in endosomes and lysosomes after cellular intake [157]. Therefore the intrinsic stability of CaP NPs in bloodstream combined to their pH-triggered, dissolution/drug release make them perfect nano-vectors for numerous drug delivery applications.

The main drawbacks of CaP NPs are their lower drug payload values in comparison to hollow organic NPs or liposomes, and their higher tendency to form aggregates in aqueous suspensions. The formation of agglomerations can hinder their penetration into cells and could lead to an immediate macrophage capture and clearance. However, several works have demonstrated that the surface decoration with ionic organic molecules (e.g. citrate ions, amino acids or macromolecules) can stabilize CaP NPs in their colloidal form [141,142,158,168,169]. Another common issue of CaP NPs is that their rapid surface degradation could lead to a burst release of the payload in the organism hindering their use for some applications requiring a more sustained and prolonged release [170–172]. To overcome this problem, CaP NPs can be engineered to encapsulate the drug within the crystalline matrix (the loading values may vary significantly with the chemistry of the drug) preventing the burst release effect [21,119,120,158,170,172,173].

Applications as nano-carrier

A huge number of therapeutic agents has been loaded on the surface of CaP NPs or even encapsulated inside them. As cancer treatment is one of the greatest challenge to modern medicine and as the use of NPs as carriers can attenuate the side effects connected with the administration of highly cytotoxic drugs, NPs are often conjugated with antitumor drugs. The most employed chemotherapeutic agents loaded onto CaP NPs are doxorubicin [157,174–177], platinum complexes [139,178–182], and methotrexate [183,184]. CaP NPs were also loaded with bisphosphonates (BPs), a class of drugs based on a P–C–P backbone (where C is a carbon and P a phosphonate moiety) having high affinity for bone apatite [119,185,186]. BPs have been widely used for skeletal diseases (osteoporosis, osteosarcoma, etc.) since the last 40 years [119,139,187–192] and are conventionally dispensed by oral administration or intravenous injection. However, undesirable side effects such as fever, ulcers, or osteonecrosis of the jaw are
Table 1. Main features of targeted CaP NPs selected in this review, reported in chronological order.

| CaP NPs description                  | Application                        | Targeting agent                                                                 | Functionalization strategy                   | Reference |
|--------------------------------------|------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------|-----------|
| Polymer-coated CaP NPs              | Plasmid DNA delivery               | Galactose (asialoglycoprotein of liver cells)                                   | Formation of amide bond with the surfactant polymer | [207]     |
| Stillery coated CaP NPs              | Suicide gene delivery              | Enhanced CEA nucleotide promoter (carcinobryonic antigen of gastric cancer)     | Physiorption                                  | [231]     |
| Stillery coated CaP NPs              | Suicide gene delivery combined with produg delivery | Enhanced CEA nucleotide promoter (carcinobryonic antigen of gastric cancer) | Physiorption                                  | [232]     |
| Stillery coated CaP NPs              | Cancer imaging                     | Folic acid (cancer folate receptor)                                            | Formation of amide bond with the surfactant | [233]     |
| Stillery coated CaP NPs              | siRNA delivery                     | Anisamide (cancer Sigma-1 receptor)                                            | Insertion of targeted DSPE-PEG in the lipid layer | [234]     |
| CaP/silicate NPs                     | Cancer imaging                     | Transferrin (cancer transferrin receptor), anti-CD71 mAbs (cancer transferrin receptor), gastrin peptide (cancer gastrin receptor), pentagastrin peptide (cancer gastrin receptor) | Biotin-avidin conjugation, formation of amide bond with the surfactant | [235]     |
| CaP/silicate NPs                     | Leukemia imaging and photodynamic therapy | Several monoclonal antibodies, among them anti-CD11c mAbs (dendritic cells receptor) | Formation of amide bond with the surfactant | [236]     |
| Polymer- and silica-coated CaP NPs   | Imaging and DNA delivery           | Anti-CD117 antibody (leukemia receptor), anti-CD96 mAbs (leukemia receptor)     | Formation of amine-SMCC-thiol bond with the silica shell | [237]     |
| Stillery coated CaP NPs              | siRNA delivery                     | Anisamide (cancer Sigma-1 receptor)                                            | Insertion of targeted DSPE-PEG in the lipid layer | [238]     |
| Cobalt ferrite/CaP/polymer composite NPs | Imaging and drug delivery     | Folic acid (cancer folate receptor)                                            | Formation of amide bond with the surfactant | [239]     |
| Stillery coated CaP NPs              | siRNA delivery                     | Anisamide (cancer Sigma-1 receptor)                                            | Insertion of targeted DSPE-PEG in the lipid layer | [240]     |
| Stillery coated CaP NPs              | Drug delivery                      | DO-24 mAbs (Met/HGF receptor of cancer cells)                                  | Physiorption                                  | [177]     |
| Stillery coated CaP NPs              | Plasmid DNA and peptide delivery   | Galactose (asialoglycoprotein of liver cells)                                   | Insertion of targeted DSPE-PEG in the lipid layer | [241]     |
| Stillery coated CaP NPs              | B-cells activation                 | Hen egg lysozyme antigen (HEL-specific B-cell receptor)                         | Formation of amine-SMCC-thiol bond with the silica shell | [242]     |
| Stillery coated CaP NPs              | Cancer imaging                     | Folic acid (cancer folate receptor)                                            | Physiorption                                  | [243]     |
| Stillery coated CaP NPs              | Two-fold imaging and drug delivery | As1411 aptamer (nucleolin cell surface protein of cancer cells)                | Physisorption                                  | [136]     |
| Stillery coated CaP NPs              | siRNA delivery                     | Hyaluronic acid (cancer CD44 receptor)                                         | Formation of amide bond with the surfactant | [244]     |
| Stillery coated CaP NPs              | Imaging and photodynamic therapy   | RGDF peptide (integrins of cancer endothelial cells)                            | Formation of amine-SMCC-thiol bond with the silica shell | [245]     |
| Stillery coated CaP NPs              | Drug delivery                      | Hyaluronic acid (cancer CD44 receptor)                                         | Formation of amide bond with the surfactant | [246]     |
| Stillery coated CaP NPs              | Drug delivery                      | Alendronate (bone hydroxyapatite)                                             | Bisphosphonate displacement of phospho- | [247]     |
| Stillery coated CaP NPs              | Drug delivery                      | Hyaluronic acid (cancer CD44 receptor)                                         | phate ions from the NP surface               | [248]     |
| Stillery coated CaP NPs              | B-cells activation                 | Hen egg lysozyme antigen (HEL-specific B-cell receptor)                         | Self-assembly with surfactant                | [249]     |
| Stillery coated CaP NPs              | Drug delivery                      | Medronate (bone hydroxyapatite)                                                | Bisphosphonate displacement of phos- | [250]     |

connected to these two administration routes; in addition low BPs bioavailability is commonly observed for oral administration [193]. To avoid these side effects and to increase BPs bioavailability, the development of new strategies employing alternative administration routes mediated by CaP NPs becomes even more interesting.

Similar to BPs, the study of the interactions between bone morphogenetic proteins (BMPs) and CaP NPs is of great biological and medical interest as BMPs have been attempted to be applied for the reconstruction of bone defects resulting from trauma, surgical resection of tumors, and congenital anomalies in orthopedic and maxillofacial surgery [122,194–198]. BMPs are cytokines with a strong effect on bone and cartilage growth and with important roles during embryonic patterning and early skeletal formation [194,199]. The main role of a delivery system for BMPs is to retain these growth factors at the site of injury for a prolonged time frame, possibly also providing an initial support to which cells attach and form regenerated tissue. Furthermore, the nano-carrier should protect the BMPs from degradation and maintain its bioactivity whilst releasing the protein in a time- and space-controlled way to promote the formation of new bone at the treatment site [194]. Therefore, thanks to their osteoconductivity property, CaP NPs are ideal delivery systems for BMPs. The interaction mechanism that can occur between BMPs and CaP NPs has been studied by computer simulation, proving that the atomic-level morphology of CaP NPs significantly affects the interaction between proteins and NPs, and that the orientation of BMPs influences their adsorption–desorption behavior [200,201]. The in vitro absorption and release kinetics of BMPs from CaP NPs has been studied showing a sustained release profile of BMPs over 15 days [202]. Another interesting work by Rohanizadeh and Chung has reported three different methods to load BMPs on CaP: (i) incorporation of BMPs during hydroxyapatite precipitation, (ii) hydroxyapatite immersion in BMPs solution, and (iii) BMPs incorporation during dicalcium phosphate dihydrate conversion to hydroxyapatite. The highest BMPs uptake was achieved using the immersion method, while the BMPs loading during hydroxyapatite
adsorption of targeting molecules [121,177,206,213,214]. Apart their surface allows an efficient and stable electrostatic-driven vectors in gene therapy [124,145,203 of CaP NPs for applications non-related to bone was as non-viral bone diseases.

rier for BMPs delivery systems for the management of results suggest that CaP NPs has the potential to function as a carrier for BMMs delivery systems for the management of bone diseases.

CaP NPs were also extensively studied to encapsulate and deliver DNA/RNA, and to the best of our knowledge, the first use of CaP NPs for applications non-related to bone was as non-viral vectors in gene therapy [124,145,203–212].

CaP NPs do not possess intrinsic target specificity, apart from that mediated by EPR in cancer therapy. However, the high density of positive (Ca$^{2+}$) and negative (PO$_4^{3-}$ or OH$^-$) charges on their surface allows an efficient and stable electrostatic-driven adsorption of targeting molecules [121,177,206,213,214]. Apart from physisorption, targeting moieties can be bound to the CaP NPs surface also by the formation of covalent bonds [113,215,216].

Several molecules can be integrated in the targeting agent to achieve a strong binding with the CaP surface (hereafter called ligands). Since BPs can establish a firm link with surface calcium ions of CaP, they can be employed as ligands [191,217]. BPs are also ideal bone-targeting agents due to their affinity for apatite nanocrystals of calcified tissue (the so-called bone seeking agents) [218]. In fact, researchers are nowadays strongly focusing on the use of BPs for the targeted delivery to bones [185,219,220].

Small organic molecules with ionizable functional groups such as silanols, carboxylic acids, amines, thiols, or nucleotide strands display high affinity for the CaP surface [221–223], and can therefore be employed as ligands. When the ligands are attached to CaP NPs, their exposed functional groups can be further conjugated with the active targeting molecules. In this regard, ligands that can be connected with targeting agents through click reactions are particularly interesting due to their simplicity and efficiency [224,225]. Amines, thiols, carboxylates, and azides are classes of molecules suitable for these reactions.

Another well-reported strategy to bind targeting agents to CaP NPs surface exploits the avidin-biotin interaction, where the macromolecule (avidin or streptavidin) and the organic molecule (biotin) form a very stable supramolecular system. Several works have reported the successful conjugation of biotinylated CaP NPs with avidin-functionalized targeting molecules [113,226–230].

The most interesting applications of targeted CaP NPs as well as the targeting moieties and decoration methods employed so far are thoughtfully discussed in the next paragraphs.

**Targeted calcium phosphate nanoparticles**

The number of published works on targeted CaP NPs is relatively low as the application of CaP NPs in nanomedicine is in its infancy compared to other NPs such as liposomes, silica, or metallic NPs. Table 1 summarizes the most important features of the targeted CaP NPs selected in this review on the base of a large literature survey, while the main compositions are schematized in Figure 3.

**Applications**

On the base of our survey, targeted CaP NPs were mainly used for nucleic acids delivery in the forms of siRNA [234,238,240,244], plasmids or exogenous genes [207,237,241], and suicide genes [231,232]. Targeting moieties were added because they can direct the gene transfection toward the desired cells improving their therapeutic efficacy, or drive the delivery of apoptotic genes or siRNAs to malignant cells. The works on this topic have proved that the targeted transfection of therapeutic nucleotides or suicide genes by CaP NPs was efficient and selective. In particular, it was reported that cancer cells like the human colon cancer cells LoVo [232] and human gastric cancer cells SGC7901 [231] were selectively eradicated with suicide genes. SiRNAs were delivered to human lung cancer cells NCI-H-460 [234,240], murine melanoma cells B16F10 [238] and human colon carcinoma cells HT29-luc [244] resulting in the silencing of specific genes. Important cells for the immune responses like the dendritic ones in mice, were as well successfully targeted with CaP NPs [237]. Moreover, in the works of Hu et al. [241] and Roy et al. [207], it is reported the successful in vivo targeted transfection of exogenous genes toward murine hepatocyte cells. It must be mentioned that the main outcomes of these reports are only at proof of concept level and further evidences are necessary.

Targeted fluorescent CaP NPs were used as imaging agents and for photodynamic therapy. Fluorescent CaP NPs were prepared by doping with lanthanide ions such as Ce$^{3+}$, Eu$^{3+}$, Gd$^{3+}$, Tb$^{3+}$ [136,233,243], or by the encapsulation of organic fluorescent dyes like fluorescein isothiocyanate (FITC), rhodamin B isothiocyanate (RITC) and indocyanine green (ICG) [235–237,239,245]. Fluorescent CaP NPs were reported to allow the selective imaging of cancerous cells like human breast cancer cells MCF-7 [136], human breast cancer cells MDA-231 [136], human cervical epithelioid carcinoma cells HeLa [136,237,239], osteoblast cells MG-63 [237], human breast carcinoma cells T-47-D [243], and human nasopharyngeal carcinoma cells KB [233]. In addition, some of the targeted fluorescent CaP NPs have permitted the destruction of malignant cells such as murine leukemia stem cells 32D-p210-GFP [236] and human tongue-squamous epithelium carcinoma cells CAL-27 [245] through photodynamic therapy, where the cellular death is induced by a sudden release of heat after photon absorption.

The targeted delivery of conventional antineoplastic drugs like doxorubicin, platinum complexes, and methotrexate by CaP NPs was investigated by different research groups [136,177,239,246–248,250]. It was proved that doxorubicin-loaded CaP NPs can selectively kill tumor cells like MDA-231 cells [136], MCF-7 cells [136], HeLa cells [136], human gastric carcinoma cells
GTL-16 [177], and human lung cancer cells A549 [246]. CaP NPs carrying platinum complexes have shown high toxicity toward targeted cancer cells as HeLa [239] and A549 cells [248], while methotrexate-loaded CaP NPs demonstrated the capability to inhibit the growth of MCF-7 [245] and HeLa cells [247] with a similar efficacy to the free drug.

A very promising and original approach was reported by Temchura et al. [242] and Zilker et al. [249], that targeted CaP NPs stimulated the differentiation of selected B-cells into antibody secreting plasma cells; the targeting moiety was the hen egg lysozyme protein (HEL) that recognizes and activates the anti-HEL B-cells. According to the results of these works, targeted CaP NPs could be potentially used to stimulate immune response in patients without the involvement of microbial agents.

**Targeting agents**

All of the most employed targeting moieties in nanomedicine as mAbs, peptides, carbohydrates, transferrin, aptamers, small organic molecules, and antigens have been conjugated to CaP NPs, with mAbs having the lion’s share [177,235–237]. For example, in the work of Iafisco et al. [177] CaP NPs were functionalized with mAbs specific for the Met/Hepatocyte growth factor receptor (Met/HGFR), which is over-expressed on different types of carcinomas; therefore, the functionalized NPs were internalized only in the human gastric carcinoma cell line GTL-16 that overexpress the Met/HGFR (Figure 4). Other papers report that murine dendritic cells [237], murine leukemia stem cells 32D-p210-GFP [236] and human metastatic breast cancer cells MDA-MB-231 [235] were successfully targeted by CaP NPs functionalized with the proper mAbs.

Small organic targeting moieties have been also attached to CaP NPs; among them it is worth to mention galactose because it is a good targeting agent for a variety of hepatic diseases [207,241]. In this respect, CaP NPs functionalized with galactose were efficiently delivered to hepatocytes [207]; moreover, galactose was found to promote CaP NPs uptake by these cells [241].

Folic acid is a targeting molecule that has been extensively studied in conjunction with CaP NPs [233,239,243,251] since the folic acid receptor is overexpressed in several cancerous cells [72,92,93]. Ashokan et al. [233] reported that folic acid-functionalized CaP NPs (red emitting NPs in Figure 5) accumulate selectively on the surface of human nasopharyngeal carcinoma KB cells that overexpress the folic acid receptor, while in the case of mouse fibroblast L929 and cancer cell line A549 having normal or very low expression level of folic acid receptor, even after 4 h of incubation, the red emitting folic acid-functionalized CaP NPs were randomly distributed all around the cell without any specific interaction with the membrane (Figure 5). Similar results were found by other authors that employed folic acid as targeting agent for CaP NPs and recorded targeting activity toward human breast carcinoma cells T-47-D [243] and human cervical epithelioid carcinoma cells HeLa [239]. It was also found that folic acid promotes NPs internalization into these cancerous cells [239,243].

As mentioned above, BPs can be employed as bone seeking agents because of their high affinity for bone [247,250]. In this respect, in a recent work of Chu et al. [247] alendronate has been used both as targeting molecule for bone metastases and as CaP NPs binding ligand. Specifically, alendronate was located at the head and tail of a PEG polymer chain (i.e. alendronate-PEG-alendronate), then one alendronate moiety was employed to interact with CaP surface, while the other one acted as targeting moiety for the bone tissue. In the work of Wu et al. [250] was proved that medronate can target murine osteosarcoma cells K7M2. Moreover, medronate was found to enhance the action of a chemotherapeutic drug (JQ1, a thienotriazolodiazepine) loaded onto CaP NPs.

CaP NPs were also functionalized with anisamide [234,238,240], a benzamide derivative that interacts with the Sigma-1 receptor of neoplastic cells whose effectiveness as targeting molecule is a matter of debate [252]. However, some of the works in the literature affirm that anisamide efficiently acts as targeting agent toward human lung cancer cells NCI-H-460 [231,233], murine melanoma cells B16F10 [232] and human colon carcinoma cells HT29-luc [244] allowing CaP NPs to deliver siRNAs.
Hyaluronic acid is one of the macromolecular targeting moieties used in combination with CaP NPs [244,246,248], with the aim to target the transmembrane glycoprotein CD44 [100, 101]. In vitro experiments have highlighted that hyaluronic acid is an efficient targeting agent toward cells rich of CD44 receptors such as human lung cancer cells A549 [246,248]. In addition, these works have proved that hyaluronic acid stimulates also the CD44-mediated endocytosis of CaP NPs [246,248].

Another common targeting macromolecule that has been also functionalized to CaP NPs is transferrin. However, Barth et al. [235] reported that the transferrin receptor-targeted CaP NPs were ineffective in an in vivo model with human metastatic breast cancer cells MDA-MB-231. To explain these results, authors supposed that the target receptors in the cells were saturated by endogenous transferrin, making the binding site unavailable for the transferrin conjugated NPs.

Peptides are an important class of molecules, which can confer targeting ability to CaP NPs [235,245]. CaP NPs were conjugated with a RGD tripeptide (variant RGDfK), which is highly selective for the integrins of the endothelium of angiogenic blood vessels [89]. The authors have proved that the RGDfK peptide promotes in vivo the local enrichment of CaP NPs toward human tongue–squamous epithelium carcinoma cells CAL-27 [245]. Gastrin peptide, a macromolecule involved in the digestion mechanism, together with its synthetic equivalent pentagastrin peptide, was employed successfully by Barth et al. to CaP NPs to target in vivo human pancreatic cancer cells BxPC-3 [235].

Regarding the use of nucleic acids and their derivatives as targeting moieties for CaP NPs, two works have reported the use of a tailored nucleotide capable of being recognized by the carcinoembryonic antigen (CEA) gene and to promote gene delivery. The delivery was achieved with high effectiveness toward human colon cancer cells LoVo [232] and human gastric cancer cells SGC7901 [231]. In the interesting work by Zhou et al. [136], an oligonucleotide aptamer was chosen as targeting molecule showing a good cell targeting and CaP NPs internalization in the human cervical epithelioid carcinoma cells HeLa.

Functionalization strategies

Several surface decoration methods have been used to conjugate targeting agents to the CaP NPs surface. Even if physisorption is the simplest strategy, several concerns are raised on the arrangement of the targeting moieties onto the NP surface. However, all the works cited in this review employing physisorption strategies [64,136,231,243] have reported a successful and efficient targeting effect of CaP NPs.

An interesting physical decoration method that was used with lipid-coated CaP NPs consists of the intercalation of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-PEGylated (DSPE-PEG) into a surface lipid bilayer [234,238,240,241]. This simple approach allows the production of well-oriented targeting molecules, but it is limited only to lipid-coated CaP NPs.

Figure 5. Fluorescence microscopy images showing interaction of folic acid-functionalized CaP NPs (possessing red fluorescence) with normal fibroblast cell line L929 after (a) 1 h, and (b) 4 h of incubation, with lung cancer cell line A549 after (c) 1 h, and (d) 4 h of incubation and with folate receptor positive human nasopharyngeal carcinoma cell line KB after (e) 1 h, and (f) 4 h of incubation. From Ashokan et al. 2010 with permission from Elsevier. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article).
The targeting of CaP NPs was also achieved by exploiting the biotin-avidin non-covalent interaction [235]. However, this approach is hampered by the additional conjugation steps required to achieve biotin/avidin conjugated targeting molecules.

The most used methods to chemically bond targeting molecules to the surface of CaP NPs involve the formation of an amide or of an amine-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate-thiol bond. Both these methods are click reactions that require a ‘promoter’ molecule. In the first case, the amide bond is formed between an amine and a carboxylic acid, and it is promoted by the use of carbodiimides [207,233,235,236, 239,244,246]. In the second case, the conjugation between amines and thiols is promoted by a crosslinking agent, the succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) [237,242, 245,249]. Both methods are highly selective and allow a good reaction yield, with the disadvantages of being 2-step reactions and of using not environmentally friendly reagents [113].

Future approaches and perspectives

Targeted nanomedicine is a fascinating multidisciplinary topic that combines chemistry, physics, material sciences, nanotechnology, drug delivery, and pharmacology. However, the development of efficient targeted NPs is an extremely complex and expensive process. It is clear that a product of such laborious and complicated synthetic procedure may be very expensive and difficult to produce at the industrial scale [253]. Indeed, the addition of new functionalities means supplementary synthetic steps and costs, more convoluted behaviors and effects when administered in vivo, and also onerous regulatory hurdles to be overcome [253]. Therefore, the final product must bring significant and tangible benefits from the targeting approach in order to be translated from the bench to the market. However, we expect that following the costs/benefits principle a good number of successful applications for targeted nanomedical systems will be generated in the next years.

In this regard, CaP NPs for targeted nanomedicine are very versatile and open up a multitude of possible applications. Even if the development of CaP NPs in nanomedicine has begun only a decade ago, several therapeutic formulations have been already tested, spanning from gene to drug delivery, vaccines and advanced theranostic agents.

Apart from molecular targeting strategies, CaP NPs are also interesting materials for alternative targeting approaches such as magnetic driving. In this respect, several recent studies reported on the obtainment of magnetic CaP NPs by doping with iron oxides [160,164,165,176,254–257] or by the encapsulation of iron oxide phases [258–263]. Magnetic CaPs can be remotely controlled in the organism by employing external magnetic fields [28,164, 264,265]. The active targeting of CaP NPs by magnetic guidance offers the possibility to accumulate the nano-carriers in the diseased region, at the same time circumventing laborious and time-consuming conjugation reactions with targeting molecules. On the other hand, the magnetic driving is a very complicated task due to the need of complex devices generating magnetic fields with appropriate precision and intensity for the in vivo driving of magnetic NPs [266].

Disclosure statement

The authors declare no competing financial interests.

Funding

This work was supported in part by the European Union’s Horizon 2020 research and innovation program under grant agreement [No 720834] and by the Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) under the Flagship Project [PNR-CNR 2011–2013] NanoMAX-miRnano.

ORCID

Lorenzo Degli Esposti http://orcid.org/0000-0002-6596-560X

Alessio Adamiano http://orcid.org/0000-0002-2077-0411

Anna Tampieri http://orcid.org/0000-0003-3910-3157

Michele Iafisco http://orcid.org/0000-0002-7813-8347

References

[1] Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19: 311–330.

[2] Wagner V, Dullaart A, Bock A-K. The emerging nanomedicine landscape. Nat Biotechnol. 2006; 24:1211–1217.

[3] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653–664.

[4] Doane TL, Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev. 2012;41:2885–2911.

[5] Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles; Theory to practice. Pharmacol Rev 2001;53:283–318.

[6] Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65–81.

[7] Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161–171.

[8] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20.

[9] Pietronave S, Iafisco M, Locarno D, et al. Functionalized nanomaterials for diagnosis and therapy of cancer. J Appl Biomater Biomech 2009;7:77–89.

[10] Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.

[11] Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771–782.

[12] Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–905.

[13] Zhang Y-W, Shi J, Li Y-J, et al. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp. 2009;57:435–445.

[14] Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–466.

[15] Yao X, Panichpals K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115–124.

[16] Kabir N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73: 994–1007.

[17] West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am. 1997;23:883–915.

[18] McCarthy JR. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv Drug Deliv Rev. 2010;62:1023–1030.
[19] Agulla J, Brea D, Campos F, et al. In vivo theranostics at the peri-infarct region in cerebral ischemia. Theranostics 2013;4:90–105.

[20] Godin B, Sakamoto JH, Serda RE, et al. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci. 2010;31:199–205.

[21] Miragoli M, Ceriotti P, Iafisco M, et al. Inhalation of peptide-loaded nanoparticles improves heart failure. Sci Transl Med 2018;10:eaaan6205.

[22] Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761–769.

[23] Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58:1532–1555.

[24] Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62:1064–1079.

[25] von Maltzahn G, Park J-H, Agrawal A, et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 2009;69:3892–3900.

[26] Norman RS, Stone JW, Gole A, et al. Targeted photothermal lysis of the pathogenic bacteria, Pseudomonas aeruginosa, with gold nanorods. Nano Lett. 2008;8:302–306.

[27] Banobre-López M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep Pract Oncol Radiother. 2013;18:397–400.

[28] Zarepour A, Zarrabi A, Khosravi A. SPIONs as nanotheranostics agents. In: Zarepour A, Zarrabi A, Khosravi A, editors. SPIONs as Nano-Theranostics Agents. Singapore: Springer; 2017. p. 1–44.

[29] Chen W-H, Luo G-F, Qiu W-X, et al. Mesoporous silica-based versatile theranostic nanoplatform constructed by layer-by-layer assembly for excellent photodynamic/chemotherapy. Biomaterials 2017;117:54–65.

[30] Satterlee AB, Yuan H, Huang L. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. J Control Release. 2015;217:170–182.

[31] Mi P, Dewi N, Yanagie H, et al. Hybrid calcium phosphate-polymeric micelles incorporating gadolinium chelates for imaging-guided gadolinium neutron capture tumor therapy. ACS Nano. 2015;9:5913–5921.

[32] Chapman S, Dobrovolskaia M, Farahani K, et al. Nanoparticles for cancer imaging: the good, the bad, and the promise. Nano Today. 2013;8:454–460.

[33] Neuberger T, Schönß B, Hofmann H, et al. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005;293:483–496.

[34] de Rosales RTM. Potential clinical applications of bimodal PET-MRI or SPECT-MRI agents. J Label Compd Radiopharm. 2014;57:298–303.

[35] Pansare VJ, Hejazi S, Faenza WJ, et al. Review of long-wavelength optical and NMR imaging materials: contrast agents, fluorophores, and multifunctional nano carriers. Chem Mater. 2012;24:812–827.

[36] Xie J, Chen K, Huang J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010;31:3016–3022.

[37] Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjugate Chem. 2011;22:1879–1903.

[38] Del Vecchio S, Zannetti A, Fonti R, et al. Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 2007;51:152.

[39] Degli Esposti L, Carella F, Iafisco M. Inorganic nanoparticles for theranostic use. In: Guarino V, Ambrosio L, editors. Electrophysical and electronic technologies (EFDTs) for biomaterials and medical devices. Sawston: Woodhead-Elsevier; 2017.

[40] Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–304.

[41] Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001;19:491–496.

[42] Singh N, Jenkins GJS, Asadi R, et al. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010;1:5358.

[43] Stroh A, Zimmer C, Gutzeit C, et al. Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages. Free Radic Biol Med. 2004;36:976–984.

[44] Doshi N, Mitragotri S. Designer biomaterials for nanomedicine. Adv Funct Mater. 2009;19:3843–3854.

[45] Maeda H, Nakamura H, Fang J. The EPR effect for macro-molecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–79.

[46] Nichols JW, Bae YH. EPR: evidence and fallacy. J Control Release. 2014;190:451–464.

[47] Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 2016;244:108–121.

[48] Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48:416–427.

[49] Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. In: Schäfer-Korting M, editor. Drug delivery. Berlin, Heidelberg: Springer; 2010. p. 3–53.

[50] Toporkiewicz M, Meissner J, Matusewicz L, et al. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomed 2015;10:1399–1414.

[51] Stewart B, Wild CP. World cancer report 2014. Health. 2017. Available from: http://www.thehealthwell.info/node/725845.

[52] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 V1.0. Estimated cancer incidence, mortality and prevalence worldwide: IARC CancerBase No. 11 [Internet]. 2012. Available from: http://globocan.iarc.fr.

[53] Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Del Rev. 2014;66:2–25.

[54] Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanoparticles for anti-cancer drug delivery. J Control Release. 2010;148:135–146.

[55] Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012;2:3.

[56] Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306–332.

[57] Dang L, Liu J, Li F, et al. Targeted delivery systems for molecular therapy in skeletal disorders. JMS. 2016;17:428.
[58] Wang X, Yang Y, Jia H, et al. Peptide decoration of nanovehicles to achieve active targeting and pathology-responsive cellular uptake for bone metastasis chemotherapy. Biomater Sci. 2014;2:961–971.

[59] Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmocol Res. 2010;62:90–99.

[60] Dehaini D, Fang RH, Zhang L. Biomimetic strategies for targeted nanoparticle delivery. Bioeng Transl Med. 2016;1:30–46.

[61] Ramzy L, Nasr M, Metwally AA, et al. Cancer nanotheranostics: a review of the role of conjugated ligands for overexpressed receptors. Eur J Pharm Sci. 2017;104:273–292.

[62] Shaghnnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012;345:e8346.

[63] Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126.

[64] Zhang X-X, Eden HS, Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrate. J Control Release. 2012;159:2–13.

[65] Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol. 2010;2:326–337.

[66] Dua P, Kim S, Lee D-K. Nucleic acid aptamers targeting cell-surface proteins. Methods. 2011;54:215–225.

[67] Qian ZM. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002;54:561–587.

[68] Daniels TR, Delgado T, Helguera G, et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121:159–176.

[69] Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820:291–317.

[70] Irache JM, Salmon HH, Gamazo C, et al. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv. 2008;5:703–724.

[71] Campbell IG, Jones TA, Foulkes WD, et al. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329–5338.

[72] Chen C, Ke J, Zhou XE, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature 2013;500:486.

[73] Johnston APR, Kamphuis MMJ, Such GK, et al. Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules. ACS Nano. 2012;6:6667–6674.

[74] Brissette R, Prendergast J, Goldstein N. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel 2006;9:363–369.

[75] Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10:345–352.

[76] Koivunen E, Arap W, Rajotte D, et al. Identification of receptor ligands with phage display peptide libraries. J Nucl Med 1999;40:883.

[77] Marasco D, Perretta G, Sabatella M, et al. Past and future perspectives of synthetic peptide libraries. CPPS. Curr Cpps. 2008;9:447–467.

[78] Smith GP, Petrenko VA. Phage display. Chem Rev. 1997;97:391–410.

[79] Janas T, Janas T. The selection of aptamers specific for membrane molecular targets. Cell Mol Biol Lett 2010;16:25.

[80] Stoltenburg R, Reinemann C, Strehlitz B. SELEX—a (r) evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007;24:381–403.

[81] Gu FX, Karnik R, Wang AZ, et al. Targeted nanoparticles for cancer therapy. Nano Today. 2007;2:14–21.

[82] Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Annu Rev Biochem. 1999;68:611–647.

[83] Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012;6:696–704.

[84] Zhang K, Safah K, Tang L, et al. A novel aptamer developed for breast cancer cell internalization. ChemMedChem 2012;7:79–84.

[85] Zhou J, Rossi JJ. The therapeutic potential of cell-internalizing aptamers. Curr Opin Chem Biol. 2009;13:1144–1157.

[86] Bouchard P, Hutabarat R, Thompson K. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010;50:237–257.

[87] Keefe AD, Cloud ST. SELEX with modified nucleotides. Curr Opin Chem Biol. 2008;12:448–456.

[88] Brown KC. New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. Curr Opin Chem Biol. 2000;4:16–21.

[89] Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol Pharmaceutics. 2012;9:2961–2973.

[90] Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membrane Biol. 2014;247:291–307.

[91] McCarthy JR, Bhaumik J, Karver MR, et al. Targeted nanogels for the detection of cancers. Mol Oncol. 2010;4:511–528.

[92] Garcia-Bennett A, Nees M, Fadeel B. In search of the holy grail: folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol. 2011;81:976–984.

[93] Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5:309–319.

[94] Thorstensen K, Romso I. The role of transferrin in the mechanism of cellular iron uptake. Biochem J. 1990;271:1.

[95] Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999;31:1111–1137.

[96] Thorstensen K, Romso I. The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand J Clin Lab Invest. 1993;53:113–120.

[97] Hashida M. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev. 2001;52:187–196.

[98] Rensen PCN, Sliedregt LAJM, Ferns M, et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem. 2001;276:37577–37584.

[99] Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharmaceutics. 2008;5:474–486.

[100] Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23:605–618.

[101] Saravanakumar G, Deepagan VG, Jayakumar R, et al. Hyaluronic acid-based conjugates for tumor-targeted drug delivery and imaging. J Biomed Nanotechnol. 2014;10:17–31.

[102] Arpicco S, Milla P, Stella B, et al. Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment. Molecules. 2014;19:3193–3230.
[103] Ogawa M, Kosaka N, Choyke PL, et al. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 2009;69:1268–1272.

[104] Hu C-MJ, Kaushal S, Cao HST, et al. Half-antibody functionalized lipid – polymer hybrid nanoparticles for targeted drug delivery to carcinomaembryonic antigen presenting pancreatic cancer cells. Mol Pharmaceutics. 2010;7:914–920.

[105] Shen C, Lan X, Lu X, et al. Site-specific surface functionalization of gold nanorods using DNA origami clamps. J Am Chem Soc. 2016;138:1764–1767.

[106] Polito L, Monti D, Caneva E, et al. One-step bioengineering of magnetic nanoparticles via a surface diazo transfer/azide–alkyne click reaction sequence. ChemComm 2008;621–623.

[107] Brennan JL, Hatzakis NS, Tshikhudo TR, et al. Bionanoconjugation via click chemistry: the creation of functional hybrids of lipases and gold nanoparticles. Bioconjugate Chem. 2006;17:1373–1375.

[108] Kamphuis MMJ, Johnston APR, Such GK, et al. Targeting of cancer cells using click-functionalized polymer capsules. J Am Chem Soc. 2010;132:15881–15883.

[109] von Maltzahn G, Ren Y, Park J-H, et al. In vivo tumor cell targeting with “click” nanoparticles. Bioconjug Chem. 2008;19:1570–1578.

[110] Deshayes S, Maurizot V, Clochard M-C, et al. “Click” conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis. Pharm Res. 2011;28:1631–1642.

[111] Thorek DL, Elias eR, Tsourkas A. Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry. Mol Imaging. 2009;8:221–229.

[112] Bolley J, Guenin E, Lievre N, et al. Carbodiimide versus click chemistry for nanoparticle surface functionalization: a comparative study for the elaboration of multimodal superparamagnetic nanoparticles targeting αvβ3 integrins. Langmuir 2013;29:14639–14647.

[113] Sivaram AJ, Wardiana A, Howard CB, et al. Recent advances in the generation of antibody-nanomaterial conjugates. Adv Healthcare Mater. 2018;7:1700607.

[114] Niemeyer CM. Nanoparticles, proteins, and nucleic acids: biotechnology meets materials science. Angew Chem Int Ed. 2001;40:4128–4158.

[115] Hazarika P, Ceyhan B, Niemeyer CM. Sensitive detection of proteins using difunctional DNA–gold nanoparticles. Small 2005;1:844–848.

[116] Niemeyer CM, Ceyhan B. DNA-directed functionalization of colloidal gold with proteins. Angew Chem Int Ed. 2001;40:3685–3688.

[117] Kukolka F, Müller BK, Paternoster S, et al. A single-molecule Förster resonance energy transfer analysis of fluorescent DNA–protein conjugates for nanobiotechnology. Small. 2006;2:1083–1089.

[118] Degli Esposti L, Tampieri A, Iafisco M. Nanostructured calcium phosphates in theranostic nanomedicine. In: Uskoković V, Editor. Nanotechnologies in preventive and regenerative medicine. Amsterdam: Elsevier; 2017.

[119] Gómez-Morales J, Iafisco M, Delgado-López JM, et al. Progress on the preparation of nanocrystalline apatites and surface characterization: overview of fundamental and applied aspects. Prog Cryst Growth Charact Mater. 2013;59:1–46.
[141] Delgado-López JM, Iafisco M, Rodríguez I, et al. Crystallization of bioinspired citrate-functionalized nanocarrier with tailored carbonate content. Acta Biomater. 2012;8:3491–3499.

[142] Sandhofer B, Meckel M, Delgado-López JM, et al. Synthesis and preliminary in vivo evaluation of well-dispersed biomimetic nanocrystalline apatites loaded with positron emission tomography imaging agents. ACS Appl Mater Interfaces. 2015;7:10623–10633.

[143] Chatzipanagis K, Iafisco M, Roncal-Herrero T, et al. Crystallization of citrate-stabilized amorphous calcium phosphate to nanocrystalline apatite: a surface-mediated transformation. CrystEngComm 2016;18:3170–3173.

[144] Iafisco M, Ramírez-Rodríguez GB, Sakhno Y, et al. The growth mechanism of apatite nanocrystals assisted by citrate: relevance to bone biomineralization. CrystEngComm 2015;17:507–511.

[145] Di Mauro V, Iafisco M, Salvarani N, et al. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine 2016;11:891–906.

[146] McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60:1241–1251.

[147] Halas N. Playing with plasmons: tuning the optical resonant properties of metallic nanoshells. MRS Bull. 2005;30:362–367.

[148] Murphy CJ, Sau TK, Gole AM, et al. Anisotropic Metal Nanoparticles: synthesis, Assembly, and Optical Applications. J Phys Chem B. 2005;109:13857–13870.

[149] Cobley CM, Chen J, Cho EC, et al. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem Soc Rev. 2011;40:44–56.

[150] Arriagada F, Osseo-Asare K. Phase and dispersion stability effects in the synthesis of silica nanoparticles in a non-ion reverse microemulsion. Colloids Surf. 1992;69:105–115.

[151] Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micrometer size range. J Colloid Interface Sci. 1968;26:62–69.

[152] Cai Q, Luo Z-S, Pang W-Q, et al. Dilute solution routes to various controllable morphologies of MCM-41 silica with a basic medium. Chem Mater. 2001;13:258–263.

[153] Huo Q, Margolese DI, Stucky GD. Surfactant control of phases in the synthesis of mesoporous silica-based materials. Chem Mater. 1996;8:1147–1160.

[154] Discher DE, Eisenberg A. Polymer vesicles. Science. 2002;297:967–973.

[155] Kumar A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;75:1–18.

[156] Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1–20.

[157] Rodríguez-Ruiz I, Delgado-López JM, Durán-Olivencia MA, et al. pH-Responsive delivery of doxorubicin from citrate-apatite nanocrystals with tailored carbonate content. Langmuir. 2013;29:8213–8221.

[158] Uskoković V, Uskoković DP. Nanosized hydroxyapatite and other calcium phosphates: Chemistry of formation and application as drug and gene delivery agents. J Biomed Mater Res B. 2011;96B:152–191.

[159] Lee H, Choi HW, Kim K, et al. Modification of hydroxyapatite nanosurfaces for enhanced colloidal stability and improved interfacial adhesion in nanocomposites. Chem Mater. 2006;18:5111–5118.

[160] Boanini E, Gazzano M, Bigi A. Ionic substitutions in calcium phosphates synthesized at low temperature. Acta Biomater. 2010;6:1882–1894.

[161] Šupová M. Substituted hydroxyapatites for biomedical applications: a review. Ceram Int. 2015;41:9203–9231.

[162] Marycz K, Pazik R, Zawisza K, et al. Multifunctional nano-crystalline calcium phosphates loaded with Tetracycline antibiotic combined with human adipose derived mesenchymal stromal stem cells (hASCs). Mater Sci Eng. 2016;69:17–26.

[163] Wang Y, Wang J, Hao H, et al. In vitro and in vivo mechanism of bone tumor inhibition by selenium-doped bone mineral nanoparticles. ACS Nano. 2016;10:9927–9937.

[164] Iafisco M, Sandri M, Panseri S, et al. Magnetic bioactive and biodegradable hollow Fe-doped hydroxyapatite coated poly (I-lactic) acid micro-nanospheres. Chem Mater. 2013;25:2610–2617.

[165] Iannotti V, Adamiano A, Ausanio G, et al. Fe-doping-induced magnetism in nano-hydroxyapatites. Inorg Chem. 2017;56:4446–4458.

[166] Morgan TT, Muddana HS, Altimogl u E, et al. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett. 2008;8:4108–4115.

[167] Perera TSH, Han Y, Lu X, et al. Rare earth doped apatite nanomaterials for biological application. J Nanomater. 2015;2015:705390.

[168] Hu Y-Y, Rawal A, Schmidt-Rohr K. Strongly bound citrate stabilizes the apatite nanocrystals in bone. Proc Natl Acad Sci. 2010;107:22425–22429.

[169] Klesing J, Wiehe A, Gitter B, et al. Positively charged calcium phosphate/polymer nanoparticles for photodynamic therapy. J Mater Sci: Mater Med. 2010;21:887–892.

[170] Liu T, Chen S, Liu D, et al. On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. J Control Release. 2005;107:112–121.

[171] Yang P, Quan Z, Li C, et al. Bioactive, luminescent and mesoporous europium-doped hydroxyapatite as a drug carrier. Biomaterials. 2008;29:4341–4347.

[172] Víctor SP, Kumar TSS. Tailoring calcium-deficient hydroxyapatite nanocarriers for enhanced release of antibiotics. J Biomed Nanotechnol. 2008;4:203–209.

[173] Rohaniizadeh R, Chung K. Hydroxyapatite as a carrier for bone morphogenetic protein. J Oral Implantol. 2011;37:659–672.

[174] Víctor SP, Paul W, Jayabalan M, et al. Supramolecular hydroxyapatite complexes as theranostic near-infrared luminescent drug carriers. CrystEngComm. 2014;16:9033–9042.

[175] Víctor SP, Paul W, Jayabalan M, et al. Cucurbituril/hydroxyapatite based nanoparticles for potential use in theranostic applications. CrystEngComm. 2014;16:6929–6936.

[176] Iafisco M, Drouet C, Adamiano A, et al. Superparamagnetic iron-doped nanocrystalline apatite as a delivery system for doxorubicin. J Mater Chem B. 2016;4:57–70.

[177] Iafisco M, Delgado-Lopez JM, Varoni EM, et al. Cell surface receptor targeted biomimetic apatite nanocrystals for cancer therapy. Small. 2013;9:3834–3844.

[178] Cheng X, Kuhn L. Chemotherapy drug delivery from calcium phosphate nanoparticles. Int J Nanomed. 2007;2:667.
[179] Iafisco M, Palazzo B, Marchetti M, et al. Smart delivery of antitumoral platinum complexes from biomimetic hydroxyapatite nanocrystals. J Mater Chem. 2009;19:8385–8392.

[180] Iafisco M, Margiotta N. Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum–bisphosphonate complexes in the treatment of bone tumors: a mini-review. J Inorg Biochem. 2012;117:237–247.

[181] Barroug A, Kuhn LT, Gerstenfeld LC, et al. Interactions of cisplatin with calcium phosphate nanoparticles: in vitro controlled adsorption and release. J Orthop Res. 2004;22:703–708.

[182] Palazzo B, Iafisco M, Laforgia M, et al. Biomimetic hydroxyapatite–drug nanocrystals as potential bone substitutes with antitumor drug delivery properties. Adv Funct Mater. 2007;17:2180–2188.

[183] Mukesh U, Kulkarni V, Tushar R, et al. Methotrexate loaded self-stabilized calcium phosphate nanoparticles: a novel inorganic carrier for intracellular drug delivery. J Biomed Nanotechnol. 2009;5:99–105.

[184] Dai CF, Li SP, Li XD. Synthesis of nanostructured methotrexate/hydroxyapatite: Morphology control, growth mechanism, and bioassay explore. Colloids Surf B Biointerfaces. 2015;136:262–271.

[185] Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692.

[186] Russell R, Rogers M. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97–106.

[187] Iafisco M, Palazzo B, Falini G, et al. Adsorption and conformational change of myoglobin on biomimetic hydroxyapatite nanocrystals functionalized with alendronate. Langmuir. 2008;24:4924–4930.

[188] Pascaud P, Gras P, Coppol Y, et al. Interaction between a bisphosphonate, tiludronate, and biomimetic nanocrystalline apatites. Langmuir. 2013;29:2224–2232.

[189] Grossmann G, Grossmann A, Ohms G, et al. Solid-state NMR of bisphosphonates adsorbed on hydroxyapatite. Magn Reson Chem. 2000;38:11–16.

[190] Pascaud P, Errassifi F, Brouillet F, et al. Adsorption on apatic calcium phosphates for drug delivery: interaction with bisphosphonate molecules. J Mater Sci Mater Med. 2014;25:2373–2381.

[191] Josse S, Faucheux C, Soueidana A, et al. Novel biomaterials for bisphosphonate delivery. Biomaterials. 2005;26:2073–2080.

[192] Bosco R, Iafisco M, van den Beucken J, et al. Adsorption of alendronate onto biomimetic apatite nanocrystals to develop drug carrier coating for bone implants. In: Ishikawa K, Iwamoto Y, editors. Key Engineering Materials. – 2009;2347.

[193] Hoffmann A, Stepensky D, Ezra A, et al. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm. 2001;220:1–11.

[194] Bessa PC, Casal M, Reis R. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2:1–96.

[195] Burg KJL, Porter S, Kellam JF. Biomaterial developments for bone tissue engineering. Biomaterials. 2000;21:2347–2359.

[196] Lutolf MP, Weber FE, Schmoeckel HG, et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol. 2003;21:513–518.

[197] Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J Royal Soc Interface. 2011;8:153–170.

[198] Sheikh Z, Javaid M, Hamdan N, et al. Bone regeneration using bone morphogenetic proteins and various biomaterial carriers. Materials 2015;8:1778–1816.

[199] Bessa PC, Casal M, Reis R. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med. 2008;2:1–13.

[200] Wang Q, Wang M, Lu X, et al. Effects of atomic-level nanostructured hydroxyapatite on adsorption of bone morphogenetic protein-7 and its derived peptide by computer simulation. Sci Rep. 2017;7:15152.

[201] Dong X-L, Qi W, Tao W, et al. The dynamic behaviours of protein BMP-2 on hydroxyapatite nanoparticles. Molecular Simulation. 2011;37:1097–1104.

[202] Xie G, Sun J, Zhong G, et al. Hydroxyapatite nanoparticles as a controlled-release carrier of BMP-2: absorption and release kinetics in vitro. J Mater Sci Med. 2010;21:1875–1880.

[203] Epple M, Ganesan K, Heumann R, et al. Application of calcium phosphate nanoparticles in biomedicine. J Mater Chem. 2010;20:18–23.

[204] Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456–467.

[205] James RF, Grosveld FG. DNA-mediated gene transfer into mammalian cells. In: Walker JM, Gaaster W, editors. Techniques in molecular biology. Boston: Springer; 1987. p. 187–202.

[206] Mostaghachi B, Loretz B, Lehr CM. Calcium phosphate system for gene delivery: historical background and emerging opportunities. Cpd. 2016;22:1529–1533.

[207] Roy I, Mitra S, Maitra A, et al. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm. 2003;250:25–33.

[208] Xie Y, Chen Y, Sun M, et al. A mini review of biodegradable calcium phosphate nanoparticles for gene delivery. Cpb. 2013;14:918–925.

[209] Bish S, Bhakta G, Mitra S, et al. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int J Pharm. 2005;288:157–168.

[210] Sokolova WV, Radtke I, Heumann R, et al. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials. 2006;27:1347–1353.

[211] Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn. 2005;5:893–905.

[212] Kingston RE, Chen CA, Rose JK. Calcium phosphate transfection. Curr Protoc Mol Biol. 2003;20:3.1–20.3.8.

[213] Al-Kattan A, Girod-Fullana S, Charvillat C, et al. Biomimetic nanocrystalline apatites: emerging perspectives in cancer diagnosis and treatment. Int J Pharm. 2012;423:26–36.

[214] Zhou Z, Kennell C, Lee J-Y, et al. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomed Nanotechnol Biol Med. 2017;13:403–410.

[215] Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688–701.

[216] Mirkin CA, Niemeyer CM. Nanobiotechnology II: more Concepts and Applications. Hoboken: John Wiley & Sons; 2007.
[217] Al-Kattan A, Errassifi F, Sautereau A-M, et al. Medical potentialities of biomimetic apatites through adsorption, ionic substitution, and mineral/organic associations: three illustrative examples. Adv Eng Mater. 2010;12:8224–8233.

[218] Nadar RA, Margiotta N, Iafisco M, et al. Bisphosphonate-functionalized imaging agents, anti-tumor agents and nanocarriers for treatment of bone cancer. Adv Healthc Mater 2017;6:1601119.

[219] Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006;38:613–616.

[220] Cole LE, Vargo-Gogola T, Roeder RK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2016;99:12–27.

[221] Russo L, Taraballi F, Lupo C, et al. Carbonate hydroxyapatite functionalization: a comparative study towards (bio)molecules fixation. Interface Focus. 2014;4:20130040.

[222] Liu Q, de Wijn JR, de Groot K, et al. Surface modification of nano-apatite by grafting organic polymer. Biomaterials. 1998;19:1067–1072.

[223] Hong Z, Qiu X, Sun J, et al. Grafitng polymerization of L-lactide on the surface of hydroxyapatite nano-crystals. Polymer. 2004;45:6699–6706.

[224] Nwe K, Brechbiel MW. Growing applications of ‘click chemistry’ for bioconjugation in contemporary biomedical research. Cancer Biother Radiopharm. 2009;24:289–302.

[225] Hein CD, Liu X-M, Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res. 2008;25:2216–2220.

[226] Katz E, Willner I. Integrated nanoparticle–biomolecule hybrid systems: synthesis, properties, and applications. Angew Chem Int Ed. 2004;43:6042–6108.

[227] Hirsch JD, Eslamizar L, Filanoski BJ, et al. Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation. Anal Biochem. 2002;308:343–357.

[228] Wilchek M, Bayer EA. [3] Applications of avidin-biotin technology: literature survey. Methods Enzymol 1990;184:14–45.

[229] Diamandis EP, Christopoulos TK. The biotin-(strept) avidin system: principles and applications in biotechnology. Clin Chem. 1991;37:625–636.

[230] Haugland RP, Spence MT, Johnson I, editors. Molecular probes; Carlsbad: 66.

[231] Haukland RP, Spence MT, Johnson I. Handbook of fluorescent probes and research chemicals. In: Haugland RP, Spence MT, Johnson I, editors. Molecular probes; Carlsbad: Life Technologies; 1996.

[232] Liu T, Zhang G, Chen Y-H, et al. Tissue specific expression of suicide genes delivered by nanoparticle inhibits gastric carcinoma growth. Cancer Biol Ther. 2006;5:1683–1690.

[233] Zhang G, Liu T, Chen Y-H, et al. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res. 2009;15:201–207.

[234] Ashokan A, Menon D, Nair S, et al. A molecular receptor targeted, hydroxyapatite nanocrystal based multi-modal contrast agent. Biomaterials. 2010;31:2606–2616.

[235] Li J, Chen Y-C, Tseng Y-C, et al. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release. 2010;142:416–421.

[236] Barth BM, Sharma R, Altnooglu E, et al. Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano. 2010;4:1279–1287.

[237] Kozlova D, Chernoussova S, Kuschke T, et al. Cell targeting by antibody-functionalized calcium phosphate nanoparticles. J Mater Chem. 2012;22:396–404.

[238] Yang Y, Li J, Liu F, et al. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther. 2012;20:609–615.

[239] Rout SR, Behera B, Maiti TK, et al. Multifunctional magnetic calcium phosphate nanoparticles for targeted platin delivery. Dalton Trans. 2012;41:10777–10783.

[240] Yang Y, Hu Y, Wang Y, et al. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner. Mol Pharmaceutics. 2012;9:2280.

[241] Al-Kattan A, Santran V, Dufour P, et al. Novel contributions on luminescent aptate-based colloids intended for medical imaging. J Biomater Appl. 2014;28:697–707.

[242] Lee MS, Lee JE, Byun E, et al. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa–hyaluronic acid conjugate. J Control Release. 2014;192:122–130.

[243] Haedicke K, Kozlova D, Gräfe S, et al. Multifunctional calcium phosphate nanoparticles for combining near-infrared fluorescence imaging and photodynamic therapy. Acta Biomater. 2015;14:197–207.

[244] Kong L, Mu Z, Yu Y, et al. Polyethyleneimine-stabilized hydroxyapatite nanoparticles modified with hyaluronic acid for targeted drug delivery. RSC Adv. 2016;6:101790–101799.

[245] Chu W, Huang Y, Yang C, et al. Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis. Int J Pharm. 2017;516:352–363.

[246] Suh MS, Shen J, Kuhn LT, et al. Layer-by-layer nanoparticle platform for cancer active targeting. Int J Pharm. 2017;517:58–66.

[247] Zilker C, Kozlova D, Sokolova V, et al. Nanoparticle-based B-cell targeting vaccines: tailoring of humoral immune responses by functionalization with different TLR-ligands. Nanomedicine. 2017;13:173–182.

[248] Wu VM, Mickens J, Uskokovic V. Bisphosphonate-functionalized hydroxyapatite nanoparticles for the delivery of the bromodomain inhibitor JQ1 in the treatment of osteosarcoma. ACS Appl Mater Interfaces. 2017;9:25887–25904.

[249] Ciprest MF, Gonzalez I, da Mata MartinsTM, et al. Attaching folic acid on hydroxyapatite nanorod surfaces: an investigation of the HA–FA interaction. RSC Adv. 2016;6:76390–76400.

[250] Darşargyri A, Kümin CD, Leroux JC. Targeting nanocarriers with anisamide: fact or artifact? Adv Mater. 2017;29:160351.

[251] Cheng Z, Al Zaki A, Hui JZ, et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012; 338:903–910.

[252] Tampieri A, D’Alessandro T, Sandri M, et al. Intrinsic magnetism and hyperthermia in bioactive Fe-doped hydroxyapatite. Acta Biomater. 2012;8:843–851.
Chang K-C, Li C-Y, Hsu C-K, et al. Synthesis and properties of Fe-modified calcium-deficient hydroxyapatite nanocrystal for mri contrast agent. Biomed Eng Appl Basis Commun. 2011;23:393–401.

Panseri S, Montesi M, Sandri M, et al. Magnetic labelling of mesenchymal stem cells with iron-doped hydroxyapatite nanoparticles as tool for cell therapy. J Biomed Nanotechnol. 2016;12:909–921.

Kaygili O, Dorozhkin SV, Ates T, et al. Dielectric properties of Fe doped hydroxyapatite prepared by sol–gel method. Ceram Int. 2014;40:9395–9402.

Gou M, Li S, Zhang L, et al. Facile one-pot synthesis of carbon/calcium phosphate/Fe 3 O 4 composite nanoparticles for simultaneous imaging and pH/NIR-responsive drug delivery. Chem Commun. 2016;52:11068–11071.

Pareta RA, Taylor E, Webster TJ. Increased osteoblast density in the presence of novel calcium phosphate coated magnetic nanoparticles. Nanotechnology 2008;19:265101.

Ventura M, Sun Y, Cremers S, et al. A theranostic agent to enhance osteogenic and magnetic resonance imaging properties of calcium phosphate cements. Biomaterials 2014;35:2227–2233.

Syamchand SS, Sony G. Multifunctional hydroxyapatite nanoparticles for drug delivery and multimodal molecular imaging. Microchim Acta. 2015;182:1567–1589.

Petchsang N, Pon-On W, Hodak JH, et al. Magnetic properties of Co-ferrite-doped hydroxyapatite nanoparticles having a core/shell structure. J Magnet Mater. 2009;321:1990–1995.

Gopi D, Ansari MT, Shinyjoy E, et al. Synthesis and spectroscopic characterization of magnetic hydroxyapatite nano-composite using ultrasonic irradiation. Spectrochim Acta A Mol Biomol Spectrosc. 2012;87:245–250.

Pankhurst QA, Connolly J, Jones SK, et al. Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys. 2003;36:R167.

Dobson J. Magnetic nanoparticles for drug delivery. Drug Dev Res. 2006;67:55–60.

Clime L, Drogoff B, Zhao S, et al. Magnetic nanocarriers: from material design to magnetic manipulation. JINT. 2008;5:1268–1305.